Literature DB >> 16035032

Bone defect healing with an osteogenic protein-1 device combined with carboxymethylcellulose.

Stephen D Cook1, Samantha L Salkeld, Laura P Patron.   

Abstract

One consideration for the practical use and application of osteogenic proteins is an effective method of delivery. This study evaluated a putty-type collagen carrier with recombinant human osteogenic protein-1 (rhOP-1) ability to heal canine critical sized (2.5 cm) ulna segmental defects compared to rhOP-1 with a particulate collagen carrier (OP device). The addition of carboxymethylcellulose (CMC) to the particulate collagen carrier (OPCMC device) to form the putty consistency was evaluated in two doses (3.5 and 1.75 mg rhOP-1/g carrier). The CMC greatly improved the intraoperative handling and site containment of the device. For the one-half dose and full-dose sites there were no statistically significant differences in the radiographic grading of defect healing when treated with the particulate OP-1 device and the device with CMC added. However, there was a dose effect with greater and earlier new bone formation observed with increased rhOP-1. Mechanically, there were no differences between particulate and putty formulations, although again, a significant effect was observed for treatment dose with the full-dose OPCMC device restoring 94% of the strength of the intact ulna compared to only 65% for the identical one-half dose implant. Regardless of rhOP-1 dose, the quality of union grading and total histologic score appearance were improved with the addition of CMC, although differences in histologic scoring were not statistically significant. Overall, the radiographic, mechanical, and histologic bone-healing characteristics with the one-half dose OPCMC device were similar to sites treated with the full-dose OP device. The observed improvement in healing may allow for lesser amounts of the device or a device with less rhOP-1 to be used. (c) 2005 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16035032     DOI: 10.1002/jbm.b.30271

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  6 in total

1.  Osteogenic protein-1 delivered by hydroxyapatite-coated implants improves bone ingrowth in extracortical bone bridging.

Authors:  Neil Saran; Renwen Zhang; Robert E Turcotte
Journal:  Clin Orthop Relat Res       Date:  2010-09-28       Impact factor: 4.176

2.  Induction of fracture repair by mesenchymal cells derived from human embryonic stem cells or bone marrow.

Authors:  Anita Undale; Daniel Fraser; Theresa Hefferan; Ross A Kopher; James Herrick; Glenda L Evans; Xiaodong Li; Sanjeev Kakar; Meredith Hayes; Elizabeth Atkinson; Michael J Yaszemski; Dan S Kaufman; Jennifer J Westendorf; Sundeep Khosla
Journal:  J Orthop Res       Date:  2011-06-14       Impact factor: 3.494

3.  Use of carboxymethyl cellulose and collagen carrier with equine bone lyophilisate suggests late onset bone regenerative effect in a humerus drill defect - a pilot study in six sheep.

Authors:  Jonas Jensen; Casper Bindzus Foldager; Thomas Vestergaard Jakobsen; Kjeld Søballe; Cody Bünger; Jorgen Baas
Journal:  Open Orthop J       Date:  2010-05-11

4.  Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures.

Authors:  Neil Ghodadra; Kern Singh
Journal:  Biologics       Date:  2008-09

5.  Radiological assessment of bioengineered bone in a muscle flap for the reconstruction of critical-size mandibular defect.

Authors:  Randa Al-Fotawei; Ashraf F Ayoub; Neil Heath; Kurt B Naudi; K Elizabeth Tanner; Matthew J Dalby; Jeremy McMahon
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

Review 6.  The Role of Three-Dimensional Scaffolds in Treating Long Bone Defects: Evidence from Preclinical and Clinical Literature-A Systematic Review.

Authors:  Alice Roffi; Gopal Shankar Krishnakumar; Natalia Gostynska; Elizaveta Kon; Christian Candrian; Giuseppe Filardo
Journal:  Biomed Res Int       Date:  2017-08-09       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.